Institution view

Xuzhou Medical University

Programs currently tracked for this institution in the public Translational Deal Radar dataset.

Car Nk

allogenic CD19-CAR-NK cells

allogenic CD19-CAR-NK cells is flagged as a platform signal because it has an active early-phase oncology cell-therapy trial at Xuzhou Medical University, with a possible patent signal linked through modality_match. Manual review is still required.

Early Phase1 · Unknown

View asset